Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 16/20 | 0.40 |
| ▸ | CTRC | Q99895 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765846 | 0.96 | CMA1 (0.38) | CMA1CTRCCES2CTSG | |
| SCHEMBL30765494 | 0.91 | F3 (0.34) | CMA1CTRC | |
| SCHEMBL30765579 | 0.90 | F3 (0.39) | CMA1CTRC | |
| SCHEMBL30765987 | 0.90 | F2 (0.37) | CMA1CTRCNAMPT | |
| SCHEMBL30765604 | 0.89 | AVPR1B (0.34) | CMA1NAMPT | |
| SCHEMBL30765845 | 0.88 | TDP1 (0.36) | CMA1 | |
| SCHEMBL30765535 | 0.84 | F2 (0.34) | NAMPT | |
| SCHEMBL30765643 | 0.84 | NAMPT (0.35) | NAMPT | |
| SCHEMBL31558399 | 0.84 | CMA1 (0.36) | CMA1CTRCCTSGNAMPT | |
| SCHEMBL30765877 | 0.83 | CMA1 (0.37) | CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |